Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease
This article has been corrected.
VIEW CORRECTIONPublication: Journal of Comparative Effectiveness Research
Abstract
Aim: To compare health plan-paid costs, exacerbations and pneumonia outcomes for patients with chronic obstructive pulmonary disease (COPD) initiating combination tiotropium olodaterol (TIO + OLO) versus triple therapy (TT: long-acting muscarinic antagonist + long-acting β2 agonists + inhaled corticosteroid). Patients & methods: COPD patients initiating TIO + OLO or TT between 1 January 2014 and 30 June 2016 were identified from a managed care Medicare database and balanced for baseline characteristics using inverse probability of treatment weighting before assessment of outcomes. Results: Annual COPD-related and all-cause costs were US$4118 (35%) and US$5384 (23%) lower for TIO + OLO versus TT (both p ≤ 0.001). TIO + OLO patients had nearly half the severe exacerbations (8.3 vs 15.5%; p = 0.014) and pneumonia was also less common (18.9 vs 30.9%; p < 0.001). Conclusion: TIO + OLO was associated with improved economic and COPD health outcomes versus TT.
Supplementary Material
File (suppl_file.docx)
- Download
- 313.22 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
American Lung Association. Trends in COPD (chronic bronchitis and emphysema): morbidity and mortality (2013). http://www.lung.org/assets/documents/research/copd-trend-report.pdf
2.
Wheaton AG, Cunningham TJ, Ford ES, Croft JB, Centers for Disease Control and Prevention. Employment and activity limitations among adults with chronic obstructive pulmonary disease – United States, 2013. MMWR Morb. Mortal Wkly Rep. 64(11), 289–295 (2015).
3.
James SL, Abate D, Abate KH et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159), 1789–1858 (2018).
4.
Soriano JB, Abajobir AA, Abate KH et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 5(9), 691–706 (2017).
5.
Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged >/= 18 years in the United States for 2010 and projections through 2020. Chest 147(1), 31–45 (2015).
6.
Global Initiative for Chronic Obstructive Lung Disease, Inc. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018). https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf
•• This 2018 international consensus report (Global Initiative for Chronic Obstructive Lung Disease) provides recommendations for management of chronic obstructive pulmonary disease, which include restricting triple therapy (TT) for only the most severe patients.
7.
Dalal AA, Patel J, D'Souza A, Farrelly E, Nagar S, Shah M. Impact of COPD exacerbation frequency on costs for a managed care population. J. Manag. Care Spec. Pharm. 21(7), 575–583 (2015).
8.
Dhamane AD, Moretz C, Zhou Y et al. COPD exacerbation frequency and its association with health care resource utilization and costs. Int. J. Chron. Obstruct. Pulmon. Dis. 10, 2609–2618 (2015).
• The frequency of chronic obstructive pulmonary disease exacerbation was a major driver of real-world healthcare costs.
9.
Patel JG, Coutinho AD, Lunacsek OE, Dalal AA. COPD affects worker productivity and health care costs. Int. J. Chron. Obstruct. Pulmon. Dis. 13, 2301–2311 (2018).
10.
Dransfield MT, Bailey W, Crater G, Emmett A, O'Dell DM, Yawn B. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim. Care. Respir. J. 20(1), 46–53 (2011).
11.
Asche CV, Leader S, Plauschinat C et al. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int. J. Chron. Obstruct. Pulmon. Dis. 7, 201–209 (2012).
12.
Fitch K, Iwasaki K, Pyenson B, Plauschinat C, Zhang J. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr. Med. Res. Opin. 27(7), 1425–1429 (2011).
13.
Price D, West D, Brusselle G et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int. J. Chron. Obstruct. Pulmon. Dis. 9, 889–904 (2014).
14.
White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids – implications for safety and costs: cross-sectional observational study. PLoS ONE 8(10), e75221 (2013).
15.
Barrecheguren M, Monteagudo M, Ferrer J et al. Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir. Med. 111, 47–53 (2016).
16.
Brusselle G, Price D, Gruffydd-Jones K et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int. J. Chron. Obstruct. Pulmon. Dis. 10, 2207–2217 (2015).
• Overuse of inhaled corticosteroid-containing regimens was extensive and ultimately led to overuse of TT in primary care practice.
17.
Burgel PR, Deslee G, Jebrak G et al. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? Eur. Respir. J. 43(4), 1201–1203 (2014).
18.
Casas A, Montes de Oca M, Menezes AM et al. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Int. J. Chron. Obstruct. Pulmon. Dis. 13, 1545–1556 (2018).
19.
Safka KA, Wald J, Wang H, McIvor L, McIvor A. GOLD stage and treatment in COPD: a 500 patient point prevalence study. Chronic Obstr. Pulm. Dis. 4(1), 45–55 (2016).
20.
Simeone JC, Luthra R, Kaila S et al. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int. J. Chron. Obstruct. Pulmon. Dis. 12, 73–83 (2017).
21.
Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.(7), CD002991 (2012).
•• Meta-analysis of randomized controlled trials found that regular use of inhaled corticosteroid-containing regimens increased the risk of pneumonia by 56% over placebo.
22.
Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 8, 295–304 (2013).
23.
Flynn RW, MacDonald TM, Hapca A, MacKenzie IS, Schembri S. Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis. Respir. Res. 15, 141 (2014).
24.
Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 169(7), 855–859 (2004).
25.
Price DB, Russell R, Mares R et al. Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study. PLoS ONE 11(9), e0162903 (2016).
26.
Buhl R, Criee CP, Kardos P et al. Dual bronchodilation vs triple therapy in the ‘real-life’ COPD DACCORD study. Int. J. Chron. Obstruct. Pulmon. Dis. 13, 2557–2568 (2018).
• Patients treated with long-acting muscarinic antagonist + long-acting β2 agonist in primary and secondary care experienced exacerbations at roughly half the rate of patients treated with TT.
27.
STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol) inhalation spray for oral inhalation use [prescribing information]. Boehringer Ingelheim Pharmaceuticals, Inc., CT, USA (2018). https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Stiolto%20Respimat/stiolto.pdf
28.
Halpin DMG. The role of tiotropium + olodaterol dual bronchodilator therapy in the management of chronic obstructive pulmonary disease. Tuberc. Respir. Dis. (Seoul) 81(1), 13–18 (2018).
29.
Palli SR, Buikema AR, Korrer S et al. Comparing healthcare costs in COPD patients initiating tiotropium/olodaterol vs. triple therapy. Presented at: Academy of Managed Care Pharmacy (AMCP) Nexus. FL, USA, 22–25 October (2018).
30.
Palli SR, Kaila S, Juday T. Comparing healthcare cost and resource utilization in COPD patients initiating tiotropium/olodaterol (T/O) vs. triple therapy (TT). Presented at: 40th Annual Meeting of the Society for Medical Decision Making (SMDM). Montreal, Canada, 14–17 October (2018).
31.
Ford ES. Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample 2001–2012 and Nationwide Emergency Department Sample 2006–2011. Chest 147(4), 989–998 (2015).
32.
Jinjuvadia C, Jinjuvadia R, Mandapakala C, Durairajan N, Liangpunsakul S, Soubani AO. Trends in outcomes, financial burden, and mortality for acute exacerbation of chronic obstructive pulmonary disease (COPD) in the United States from 2002 to 2010. COPD 14(1), 72–79 (2017).
33.
Singh JA, Yu S. Utilization due to chronic obstructive pulmonary disease and its predictors: a study using the U.S. National Emergency Department Sample (NEDS). Respir. Res. 17, 1 (2016).
34.
Quan H, Li B, Couris CM et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol. 173(6), 676–682 (2011).
35.
van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med. Care 47(6), 626–633 (2009).
36.
United States, Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Medical Care. Series ID: CUUR0000SAM (2017). http://data.bls.gov/cgi-bin/surveymost?cu
37.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav. Res. 46(3), 399–424 (2011).
38.
Sturmer T, Wyss R, Glynn RJ, Brookhart MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J. Intern. Med. 275(6), 570–580 (2014).
39.
McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat. Med. 32(19), 3388–3414 (2013).
40.
Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J. Health Econ. 20(4), 461–494 (2001).
41.
Graubard BI, Korn EL. Predictive margins with survey data. Biometrics 55(2), 652–659 (1999).
42.
Langham S, Wright A, Baldwin M. Costs and outcomes of single-inhaler triple therapy compared to dual therapy with a long-acting beta agonist and long-acting muscarinic antagonist for the treatment of patients with chronic obstructive pulmonary disease in the United States. J. Manag. Care Spec. Pharm. 24(Suppl. 10-a), S70 (2018).
43.
Lipson DA, Barnhart F, Brealey N et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 378(18), 1671–1680 (2018).
44.
Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 61(3), 250–258 (2006).
45.
Papi A, Vestbo J, Fabbri L et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 391(10125), 1076–1084 (2018).
46.
Suissa S, Drazen JM. Making sense of triple inhaled therapy for COPD. N. Engl. J. Med. 378(18), 1723–1724 (2018).
47.
Petite SE. Single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 379(6), 591–592 (2018).
48.
Wedzicha JA, Banerji D, Kostikas K. Single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 379(6), 591 (2018).
49.
Bogart M, Stanford RH, Reinsch T, Hull M, Buikema A, Hulbert E. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: a retrospective study. Respir. Med. 142, 73–80 (2018).
50.
Miravitlles M, Andreu I, Romero Y, Sitjar S, Altes A, Anton E. Difficulties in differential diagnosis of COPD and asthma in primary care. Br. J. Gen. Pract. 62(595), e68–e75 (2012).
51.
Price DB, Yawn BP, Jones RC. Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care. Mayo Clin. Proc. 85(12), 1122–1129 (2010).
52.
Cazzola M. The use of triple therapy in chronic obstructive pulmonary disease and outcomes of the IMPACT trial. Eur. Respir. Pulm. Dis. 4(1), 17–18 (2018).
53.
Global Initiative for Chronic Obstructive Lung Disease, Inc. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2019 report) (2019). https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf
54.
Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am. J. Respir. Crit. Care Med. 176(2), 162–166 (2007).
55.
Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ 2, 1665 (1960).
56.
Vestbo J, Papi A, Corradi M et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 389(10082), 1919–1929 (2017).
Information & Authors
Information
Published In
Pages: 1299 - 1316
PubMed: 31559852
Copyright
© 2019 Swetha R Palli. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 18 July 2019
Accepted: 12 September 2019
Published online: 27 September 2019
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease. (2019) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2019-0101
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Asif Shaikh, John Ritz, Julian Casciano, Swetha Palli, Brendan Clark, Zenobia Dotiwala, Jennifer Quint, Clinical and Economic Evaluation of Fluticasone Furoate/Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol Therapy in Maintenance Treatment–Naive Patients with COPD in the US, International Journal of Chronic Obstructive Pulmonary Disease, 10.2147/COPD.S479504, Volume 20, (335-348), (2025).
- Wouter H van Geffen, Daniel J Tan, Julia AE Walters, E Haydn Walters, Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD011600.pub3, 2024, 2, (2023).
- Sanjay Sethi, Swetha R Palli, Lindsay G S Bengtson, Erin K Buysman, Brendan Clark, Andrew Sargent, Asif Shaikh, Gary T Ferguson, Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol, Journal of Managed Care & Specialty Pharmacy, 10.18553/jmcp.2023.22373, 29, 7, (791-806), (2023).
- Sanjay Sethi, Brendan Clark, Lindsay GS Bengtson, Erin K Buysman, Swetha Palli, Andrew Sargent, Asif Shaikh, Gary T Ferguson, Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History, International Journal of Chronic Obstructive Pulmonary Disease, 10.2147/COPD.S386962, Volume 18, (625-641), (2023).
- Sanjay Sethi, Antony Wright, Elisabeth Sophia Hartgers-Gubbels, Marlene Hechtner, Brendan Clark, Ciara Wright, Sue Langham, Roland Buhl, Costs and Clinical Consequences of Compliance with COPD GOLD Recommendations or National Guidelines Compared with Current Clinical Practice in Belgium, Germany, Sweden, and the United States, International Journal of Chronic Obstructive Pulmonary Disease, 10.2147/COPD.S371440, Volume 17, (2149-2160), (2022).
- Kostiantyn D. Dmytriiev, Yuriy M. Mostovoy, Oleksandr Dobrovanov, Nataliia S. Slepchenko, EFFICACY OF COMBINATION OF TIOTROPIUM/OLODATEROL IN PATIENTS WITH COPD IN REAL CLINICAL PRACTICE, Wiadomości Lekarskie, 10.36740/WLek202212110, 75, 12, (2953-2957), (2022).
- Swetha R Palli, Bin Xie, Benjamin Chastek, Caitlin A Elliott, Lindsay G S Bengtson, Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies, Journal of Managed Care & Specialty Pharmacy, 10.18553/jmcp.2021.20514, 27, 7, (810-824), (2021).
- Jennifer Cook, Chloe Bloom, Jen Lewis, Zoe Marjenberg, Jaime Hernando Platz, Sue Langham, Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease, Journal of Market Access & Health Policy, 10.1080/20016689.2021.1929757, 9, 1, (2021).
- Swetha R Palli, Siting Zhou, Asif Shaikh, Vincent J Willey, Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy, Journal of Managed Care & Specialty Pharmacy, 10.18553/jmcp.2021.20390, 27, 5, (625-637), (2021).
- Swetha R. Palli, Monica Frazer, Mary DuCharme, Ami R. Buikema, Amy J. Anderson, Jessica Franchino-Elder, Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy, Journal of Managed Care & Specialty Pharmacy, 10.18553/jmcp.2020.20159, 26, 10, (1363-1374), (2020).